WO2017003153A1 - Méthode de production de cellules tueuses naturelles à partir de monocytes de sang de cordon ombilical, ou de cellules dérivées de ces derniers - Google Patents
Méthode de production de cellules tueuses naturelles à partir de monocytes de sang de cordon ombilical, ou de cellules dérivées de ces derniers Download PDFInfo
- Publication number
- WO2017003153A1 WO2017003153A1 PCT/KR2016/006899 KR2016006899W WO2017003153A1 WO 2017003153 A1 WO2017003153 A1 WO 2017003153A1 KR 2016006899 W KR2016006899 W KR 2016006899W WO 2017003153 A1 WO2017003153 A1 WO 2017003153A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- natural killer
- cord blood
- cell
- hut78
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 title claims abstract description 426
- 210000000822 natural killer cell Anatomy 0.000 title claims abstract description 213
- 210000004700 fetal blood Anatomy 0.000 title claims abstract description 73
- 238000004519 manufacturing process Methods 0.000 title claims description 21
- 210000001616 monocyte Anatomy 0.000 title abstract description 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 49
- 238000000034 method Methods 0.000 claims abstract description 36
- 238000012258 culturing Methods 0.000 claims abstract description 21
- 210000005087 mononuclear cell Anatomy 0.000 claims description 66
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 40
- 239000012091 fetal bovine serum Substances 0.000 claims description 40
- 108010002350 Interleukin-2 Proteins 0.000 claims description 32
- 102000000588 Interleukin-2 Human genes 0.000 claims description 32
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 31
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 31
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 201000011510 cancer Diseases 0.000 claims description 22
- 102000003812 Interleukin-15 Human genes 0.000 claims description 21
- 108090000172 Interleukin-15 Proteins 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 18
- 102000015696 Interleukins Human genes 0.000 claims description 14
- 108010063738 Interleukins Proteins 0.000 claims description 14
- 208000035473 Communicable disease Diseases 0.000 claims description 10
- 206010025323 Lymphomas Diseases 0.000 claims description 10
- 210000002966 serum Anatomy 0.000 claims description 9
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 230000004936 stimulating effect Effects 0.000 claims description 5
- 102000013462 Interleukin-12 Human genes 0.000 claims description 4
- 108010065805 Interleukin-12 Proteins 0.000 claims description 4
- 102000003810 Interleukin-18 Human genes 0.000 claims description 4
- 108090000171 Interleukin-18 Proteins 0.000 claims description 4
- 229940127174 UCHT1 Drugs 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 108010074108 interleukin-21 Proteins 0.000 claims description 4
- 244000309466 calf Species 0.000 claims description 2
- 239000006166 lysate Substances 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 3
- 230000002147 killing effect Effects 0.000 abstract description 3
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 58
- 230000035755 proliferation Effects 0.000 description 37
- 239000002609 medium Substances 0.000 description 34
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 26
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 23
- 230000022534 cell killing Effects 0.000 description 21
- 102000003814 Interleukin-10 Human genes 0.000 description 15
- 108090000174 Interleukin-10 Proteins 0.000 description 15
- 239000008188 pellet Substances 0.000 description 15
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 14
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 14
- 239000012146 running buffer Substances 0.000 description 13
- 210000004881 tumor cell Anatomy 0.000 description 12
- 239000000872 buffer Substances 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 238000011534 incubation Methods 0.000 description 8
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 7
- 108010043610 KIR Receptors Proteins 0.000 description 7
- 102000002698 KIR Receptors Human genes 0.000 description 7
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 6
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 6
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 6
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 5
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 5
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 5
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 5
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 5
- 238000003501 co-culture Methods 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 4
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 4
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 4
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 201000005787 hematologic cancer Diseases 0.000 description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 210000004102 animal cell Anatomy 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229920002113 octoxynol Polymers 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 102100030703 Interleukin-22 Human genes 0.000 description 2
- 101150069255 KLRC1 gene Proteins 0.000 description 2
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 description 2
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101001027081 Homo sapiens Killer cell immunoglobulin-like receptor 2DL1 Proteins 0.000 description 1
- 101000945371 Homo sapiens Killer cell immunoglobulin-like receptor 2DL2 Proteins 0.000 description 1
- 101000945351 Homo sapiens Killer cell immunoglobulin-like receptor 3DL1 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102100037363 Killer cell immunoglobulin-like receptor 2DL1 Human genes 0.000 description 1
- 102100033599 Killer cell immunoglobulin-like receptor 2DL2 Human genes 0.000 description 1
- 102100033627 Killer cell immunoglobulin-like receptor 3DL1 Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
Definitions
- Figure 4a is a graph showing the proliferation rate of natural killer cells according to the number of re-stimulation when incubating the enriched natural killer cells with HuT78 support cells as seed cells.
- the re-stimulation may be repeated one or more times at intervals of 5 to 12 days starting on day 0 of the culture, preferably may be repeated one or more times at intervals of 7 days, but is not limited thereto.
- cells may be obtained 5 days after the last stimulus, preferably 14 days, but this is also not limiting.
- Tube 5 anti-human CD3-FITC, anti-human NKp44-PE (BD Pharmingen, 558563), anti-human CD56-PE-Cy5
- Natural killer cells cultured with various supporting cells were reacted with various tumor cell lines to measure direct cell killing ability.
- Inhibitory KIR analysis showed that the ratio of CD158a (-) CD158b (-) CD158e (-) cells (KIR (-) cells) of natural killer cells obtained from cells derived from cord blood mononuclear cells was higher than that of PBMC (Fig. 8b).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne une méthode pour faire proliférer et produire des cellules tueuses naturelles qui permet une production en masse de cellules tueuses naturelles à forte activité tueuse et pouvant être d'application clinique, à partir d'une petite quantité de monocytes de sang de cordon ombilical ou de cellules dérivées de ces derniers, en co-cultivant des monocytes de sang de cordon ombilical ou des cellules dérivées de ces derniers avec des cellules TCD4(+) et en les faisant proliférer, et, de ce fait, la méthode peut être utilisée dans la commercialisation d'agents thérapeutiques cellulaires dérivés de sang de cordon ombilical.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150092055 | 2015-06-29 | ||
| KR10-2015-0092055 | 2015-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2017003153A1 true WO2017003153A1 (fr) | 2017-01-05 |
Family
ID=57608675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2016/006899 WO2017003153A1 (fr) | 2015-06-29 | 2016-06-28 | Méthode de production de cellules tueuses naturelles à partir de monocytes de sang de cordon ombilical, ou de cellules dérivées de ces derniers |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2017003153A1 (fr) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107475196A (zh) * | 2017-10-09 | 2017-12-15 | 天津长和生物技术有限公司 | 自然杀伤细胞培养基质及自然杀伤细胞的扩增培养方法 |
| CN113403273A (zh) * | 2021-06-25 | 2021-09-17 | 江苏蒙彼利生物科技有限公司 | 一种扩增脐带血来源的nk细胞的培养方法 |
| CN114058584A (zh) * | 2022-01-07 | 2022-02-18 | 山东省齐鲁干细胞工程有限公司 | 一种临床用自然杀伤细胞的制备方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100045704A (ko) * | 2008-10-24 | 2010-05-04 | 주식회사 메디셀 | 제대혈로부터 효율적인 자연살해세포의 증식 및 분화 방법 |
| KR20120100207A (ko) * | 2011-03-03 | 2012-09-12 | 한국생명공학연구원 | 제대혈 ｃｄ14 양성 단핵세포로부터 자연살해세포 분화 및 증식 방법 |
| JP2013071915A (ja) * | 2011-09-28 | 2013-04-22 | Biotherapy Institute Of Japan | Ｎｋ細胞強化型血液製剤の製造方法 |
| JP2013143970A (ja) * | 2013-05-01 | 2013-07-25 | Cellex:Kk | Ｎｋ細胞活性化方法、これを用いたｎｋ細胞増殖方法及び細胞製造方法並びにｎｋ細胞を含む単核球 |
| KR20140123503A (ko) * | 2011-12-22 | 2014-10-22 | 재단법인 목암생명공학연구소 | 자연살해세포의 제조방법, 이러한 방법에 의해 제조된 자연살해세포 및 이를 포함하는 종양 및 감염성 질환 치료용 조성물 |
-
2016
- 2016-06-28 WO PCT/KR2016/006899 patent/WO2017003153A1/fr active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100045704A (ko) * | 2008-10-24 | 2010-05-04 | 주식회사 메디셀 | 제대혈로부터 효율적인 자연살해세포의 증식 및 분화 방법 |
| KR20120100207A (ko) * | 2011-03-03 | 2012-09-12 | 한국생명공학연구원 | 제대혈 ｃｄ14 양성 단핵세포로부터 자연살해세포 분화 및 증식 방법 |
| JP2013071915A (ja) * | 2011-09-28 | 2013-04-22 | Biotherapy Institute Of Japan | Ｎｋ細胞強化型血液製剤の製造方法 |
| KR20140123503A (ko) * | 2011-12-22 | 2014-10-22 | 재단법인 목암생명공학연구소 | 자연살해세포의 제조방법, 이러한 방법에 의해 제조된 자연살해세포 및 이를 포함하는 종양 및 감염성 질환 치료용 조성물 |
| JP2013143970A (ja) * | 2013-05-01 | 2013-07-25 | Cellex:Kk | Ｎｋ細胞活性化方法、これを用いたｎｋ細胞増殖方法及び細胞製造方法並びにｎｋ細胞を含む単核球 |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107475196A (zh) * | 2017-10-09 | 2017-12-15 | 天津长和生物技术有限公司 | 自然杀伤细胞培养基质及自然杀伤细胞的扩增培养方法 |
| CN113403273A (zh) * | 2021-06-25 | 2021-09-17 | 江苏蒙彼利生物科技有限公司 | 一种扩增脐带血来源的nk细胞的培养方法 |
| CN113403273B (zh) * | 2021-06-25 | 2023-04-25 | 江苏蒙彼利生物科技有限公司 | 一种扩增脐带血来源的nk细胞的培养方法 |
| CN114058584A (zh) * | 2022-01-07 | 2022-02-18 | 山东省齐鲁干细胞工程有限公司 | 一种临床用自然杀伤细胞的制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2016209021A1 (fr) | Méthode pour faire proliférer des cellules tueuses naturelles et composition pour faire proliférer des cellules tueuses naturelles | |
| AU2016274633B2 (en) | Methods for the production of TCR gamma delta+ T cells | |
| KR102575976B1 (ko) | 자연살해 세포의 증식방법 | |
| WO2016085248A1 (fr) | Procédé de culture de cellules tueuses naturelles à l'aide de lymphocytes t | |
| KR101866827B1 (ko) | 방사선 조사된 말초혈액단핵구를 이용한 고효율 자연살상세포의 제조방법 및 이를 이용한 항암 면역 세포치료제 조성물 | |
| WO2021054789A1 (fr) | Lignée de cellules nk génétiquement modifiée transduite avec un gène codant pour un nouveau récepteur d'antigène chimère et son utilisation | |
| WO2018217064A2 (fr) | Procédé de culture de cellules tueuses naturelles au moyen d'un lymphocyte t transformé | |
| WO2019182422A1 (fr) | Nouvelle lignée de cellules tueuses naturelles génétiquement modifiées et son utilisation | |
| KR20130124916A (ko) | 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법 | |
| WO2020101361A1 (fr) | Procédé de culture de cellules tueuses naturelles dérivées de sang de cordon ombilical au moyen de lymphocytes t transformés | |
| KR20200135514A (ko) | 케모카인 리셉터와 세포 접착 분자를 발현하는 cd3 음성 세포의 집단, 및 그 이용 그리고 그 제조 방법 | |
| WO2017003153A1 (fr) | Méthode de production de cellules tueuses naturelles à partir de monocytes de sang de cordon ombilical, ou de cellules dérivées de ces derniers | |
| WO2021251707A1 (fr) | Lignée cellulaire génétiquement modifiée pour l'activation et l'amplification de cellules nk et utilisation associée | |
| Carson et al. | Natural killer cell subsets and development | |
| WO2019182392A1 (fr) | Procédé de production de cellules tueuses naturelles | |
| Zhou et al. | CD123 redirected multiple virus-specific T cells for acute myeloid leukemia | |
| KR101867942B1 (ko) | 바이러스 항원 특이적인 t 세포의 유도 및 증식 방법 | |
| Rolink et al. | The potential involvement of Notch signaling in NK cell development | |
| WO2013168978A1 (fr) | Méthode d'induction et de prolifération de cellules tueuses naturelles dérivées de cellules mononucléaires du sang périphérique | |
| WO2016117960A1 (fr) | Cellules souches mésenchymateuses surexprimées par grim19 efficaces dans le traitement d'une maladie immunitaire, et leur utilisation | |
| WO2019231243A1 (fr) | Cellule nourricière exprimant ox40l et procédé de culture de cellules tueuses naturelles l'utilisant | |
| TW202134427A (zh) | 含有nk細胞之細胞集團之製造方法 | |
| WO2021177599A1 (fr) | PROCÉDÉ DE PRODUCTION DE CELLULES NK DE TYPE MÉMOIRE PRÉSENTANT UNE APTITUDE À EXPRIMER DES NIVEAUX SUPÉRIEURS DE NCR, DE CYTOTOXICITÉ ET D'IFN-γ PAR RAPPORT À DES CELLULES NK DANS LE SANG PÉRIPHÉRIQUE HUMAIN | |
| WO2020213972A1 (fr) | Cellules tueuses naturelles présentant une activité anticancéreuse accrue et leur utilisation immunothérapeutique | |
| Mou et al. | 2B4 inhibits the apoptosis of natural killer cells through phosphorylated extracellular signal-related kinase/B-cell lymphoma 2 signal pathway |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16818186 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 16818186 Country of ref document: EP Kind code of ref document: A1 |